SK Capital: It will inject capital into Swiss biopharmaceutical company SWIXX, whose valuation has exceeded 1.5 billion euros.

Zhitongcaijing · 2d ago
SK Capital: It will inject capital into Swiss biopharmaceutical company SWIXX, whose valuation has exceeded 1.5 billion euros.